220 related articles for article (PubMed ID: 27098511)
1. KIAA1522 is a novel prognostic biomarker in patients with non-small cell lung cancer.
Liu YZ; Yang H; Cao J; Jiang YY; Hao JJ; Xu X; Cai Y; Wang MR
Sci Rep; 2016 Apr; 6():24786. PubMed ID: 27098511
[TBL] [Abstract][Full Text] [Related]
2. KIAA1522 potentiates TNFα-NFκB signaling to antagonize platinum-based chemotherapy in lung adenocarcinoma.
Wang B; Jing T; Jin W; Chen J; Wu C; Wang M; Liu Y
J Exp Clin Cancer Res; 2020 Aug; 39(1):170. PubMed ID: 32854746
[TBL] [Abstract][Full Text] [Related]
3. KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.
Marabese M; Ganzinelli M; Garassino MC; Shepherd FA; Piva S; Caiola E; Macerelli M; Bettini A; Lauricella C; Floriani I; Farina G; Longo F; Bonomi L; Fabbri MA; Veronese S; Marsoni S; Broggini M; Rulli E
Oncotarget; 2015 Oct; 6(32):34014-22. PubMed ID: 26416458
[TBL] [Abstract][Full Text] [Related]
4. Down-regulated MicroRNA 148b expression as predictive biomarker and its prognostic significance associated with clinicopathological features in non-small-cell lung cancer patients.
Ghasemkhani N; Shadvar S; Masoudi Y; Talaei AJ; Yahaghi E; Goudarzi PK; Shakiba E
Diagn Pathol; 2015 Sep; 10():164. PubMed ID: 26377406
[TBL] [Abstract][Full Text] [Related]
5. Serum microRNA-365 in combination with its target gene TTF-1 as a non-invasive prognostic marker for non-small cell lung cancer.
Liu Y; Zhang G; Li H; Han L; Fu A; Zhang N; Zheng Y
Biomed Pharmacother; 2015 Oct; 75():185-90. PubMed ID: 26337230
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
[TBL] [Abstract][Full Text] [Related]
7. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
Kong F; Gao F; Chen J; Sun Y; Zhang Y; Liu H; Li X; Yang P; Zheng R; Liu G; Jia Y
Oncotarget; 2016 Aug; 7(35):56193-56199. PubMed ID: 27486880
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic features and prognostic implications of Gankyrin protein expression in non-small cell lung cancer.
Wang WP; Yan XL; Li WM; Ni YF; Zhao JB; Lu Q; Wang XJ; Sun Y; Chen P; Yan BY; Cui Y; Zhang ZP; Li XF
Pathol Res Pract; 2015 Dec; 211(12):939-47. PubMed ID: 26554593
[TBL] [Abstract][Full Text] [Related]
9. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.
Facchinetti F; Bluthgen MV; Tergemina-Clain G; Faivre L; Pignon JP; Planchard D; Remon J; Soria JC; Lacroix L; Besse B
Lung Cancer; 2017 Oct; 112():62-68. PubMed ID: 29191602
[TBL] [Abstract][Full Text] [Related]
10. Significance of DEK overexpression for the prognostic evaluation of non-small cell lung carcinoma.
Liu X; Qi D; Qi J; Mao Z; Li X; Zhang J; Li J; Gao W
Oncol Rep; 2016 Jan; 35(1):155-62. PubMed ID: 26530274
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of miR-503 expression predicate advanced mythological features and poor prognosis in patients with NSCLC.
Liu L; Qu W; Zhong Z
Int J Clin Exp Pathol; 2015; 8(5):5609-13. PubMed ID: 26191272
[TBL] [Abstract][Full Text] [Related]
12. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
13. KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer.
Nagy Á; Pongor LS; Szabó A; Santarpia M; Győrffy B
Int J Cancer; 2017 Feb; 140(4):930-937. PubMed ID: 27859136
[TBL] [Abstract][Full Text] [Related]
14. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
[TBL] [Abstract][Full Text] [Related]
15. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review.
Kim JH; Kim HS; Kim BJ
Oncotarget; 2017 Jul; 8(29):48248-48252. PubMed ID: 28525386
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
Cooper WA; Tran T; Vilain RE; Madore J; Selinger CI; Kohonen-Corish M; Yip P; Yu B; O'Toole SA; McCaughan BC; Yearley JH; Horvath LG; Kao S; Boyer M; Scolyer RA
Lung Cancer; 2015 Aug; 89(2):181-8. PubMed ID: 26024796
[TBL] [Abstract][Full Text] [Related]
18. The up-regulation of long non-coding RNA AFAP1-AS1 is associated with the poor prognosis of NSCLC patients.
Deng J; Liang Y; Liu C; He S; Wang S
Biomed Pharmacother; 2015 Oct; 75():8-11. PubMed ID: 26463625
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of PAX6 by promoter methylation is associated with poor prognosis in non small cell lung cancer.
Zhang X; Yang X; Wang J; Liang T; Gu Y; Yang D
Int J Clin Exp Pathol; 2015; 8(9):11452-7. PubMed ID: 26617874
[TBL] [Abstract][Full Text] [Related]
20. Role of high expression levels of STK39 in the growth, migration and invasion of non-small cell type lung cancer cells.
Li Z; Zhu W; Xiong L; Yu X; Chen X; Lin Q
Oncotarget; 2016 Sep; 7(38):61366-61377. PubMed ID: 27542260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
